Last reviewed · How we verify
Binimetinib Pill (binimetinib-pill)
Binimetinib is a small-molecule MEK inhibitor developed by Pfizer for oncology indications, particularly melanoma with BRAF mutations where it is approved as monotherapy or in combination with encorafenib. The drug selectively inhibits mitogen-activated protein kinase kinase (MEK1/2), blocking the MAPK/ERK signaling pathway critical for cancer cell proliferation. While approved for melanoma, Pfizer is exploring binimetinib's utility in KRAS-mutant non-small cell lung cancer (NSCLC) in combination with hydroxychloroquine, with Phase 2 data completed. The formulation referenced here—binimetinib pill—represents the oral tablet form of the established MEK inhibitor, supporting convenient patient administration compared to intravenous alternatives. Commercial significance is moderate within Pfizer's oncology portfolio, with peak sales estimates in the low-to-mid hundreds of millions annually. The pipeline expansion into KRAS-driven NSCLC addresses a significant unmet need, though competitive pressure from other MEK inhibitors and KRAS-targeted agents remains substantial.
At a glance
| Generic name | binimetinib-pill |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Rash
- Nausea
- Fatigue
- Pruritus
- Edema Face
- Vomitting
- Abdominal Pain
- ALT Increase
- Anorexia
- AST Increased
- Collitis
- Constipation
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Binimetinib Pill CI brief — competitive landscape report
- Binimetinib Pill updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI